You are here

Jon's Blog

Post date
SARS-CoV-2 RNA targets for steric blocking

Potantial targets for steric blocking on the SARS-CoV-2 genome and transcripts.

The SARS-CoV-2 RNA interactome.
Lee S, Lee YS, Choi Y, Son A, Park Y, Lee KM, Kim J, Kim JS, Kim VN. Mol Cell. 2021 Apr 27:S1097-2765(21)00327-0. doi: 10.1016/j.molcel.2021.04.022. Online ahead of print.

https://www.sciencedirect.com/science/article/pii/S1097276521003270

Monday, May 17, 2021 - 10:23
Positive control, human and mouse splice modification

Flynn LL, Mitrpant C, Adams A, Pitout IL, Stirnweiss A, Fletcher S, Wilton SD. Targeted SMN Exon Skipping: A Useful Control to Assess In Vitro and In Vivo Splice-Switching Studies. Biomedicines. 2021;9(5):552. doi:10.3390/biomedicines9050552

https://www.mdpi.com/2227-9059/9/5/552/htm

Friday, May 14, 2021 - 11:52
MO knockdown of ectopic GFP in axlotl

There are few papers reporting using a Morpholino to directly target GFP in vivo; here is one example.
Schnapp E, Tamaka EM. Quantitative evaluation of morpholino-mediated protein knockdown of GFP, MSX1, and PAX7 during tail regeneration in Ambystoma mexicanum. Dev Dyn. 2005 Jan;232(1):162-70.
https://anatomypubs.onlinelibrary.wiley.com/doi/full/10.1002/dvdy.20203

Friday, April 23, 2021 - 11:21
Oligo types, therapeutic Morpholinos, upregulation with Morpholinos

Here are some types of oligos sorted by their mechanisms.

RNase-H dependent

  • DNA
  • Phosphorothioate DNA

RNase-independent (steric blocking oligos)

  • Morpholinos
  • 2’-O-substituted oligos (often phosphorothioate linkages)
    • 2’-O methyl
    • 2’-O methoxyethyl
  • PNA (peptide nucleic acids)
  • LNA (locked nucleic acid)

Argonaute dependent

  • siRNA
  • shRNA

About the Morpholino drugs

Thursday, April 15, 2021 - 09:24
Review of oligo delivery for therapeutics

Hammond SH et al. Delivery of oligonucleotide-based therapeutics: challenges and opportunities. Embo Mol Med. 2021:e13243. doi: 10.15252/emmm.202013243

https://www.embopress.org/doi/full/10.15252/emmm.202013243

Wednesday, April 7, 2021 - 09:48
Review of mutant-morphant discrepency & genetic compensation

Salanga CM, Salanga MC. Genotype to Phenotype: CRISPR Gene Editing Reveals Genetic Compensation as a Mechanism for Phenotypic Disjunction of Morphants and Mutants. Int J Mol Sci. 2021;22(7),3472. doi:10.3390/ijms22073472
https://www.mdpi.com/1422-0067/22/7/3472

Monday, March 29, 2021 - 13:39
Papers describing Morpholinos used in DMD studies

Papers describing Morpholinos used in DMD studies
Note: this is not an exhaustive list. Using DMD-related keywords in the Morpholino publications database will turn up many more citations. Some key papers are marked with triple astrisks (***). The papers are divided into non-clinical (first) and clinical (following).

NON-CLINICAL PAPERS

Thursday, March 4, 2021 - 15:01
A description of using Morpholinos to block splice-regulatory protein binding sites

Biayna J, Mazuelas H, Gel B, Terribas E, Dumbovic G, Rosas I, Fernández-Rodriguez J, Blanco I, Castellanos E, Carrió M, Lazaro C, Serra E. Using antisense oligonucleotides for the physiological modulation of the alternative splicing of NF1 exon 23a during PC12 neuronal differentiation. Sci Rep. 2021;11(1):3661. doi:10.1038/s41598-021-83152-w

https://www.nature.com/articles/s41598-021-83152-w

Thursday, February 11, 2021 - 10:44
Review: Peptide-conjugate antisense based splice-correction for Duchenne muscular dystrophy and other neuromuscular diseases

Peptide-conjugate antisense based splice-correction for Duchenne muscular dystrophy and other neuromuscular diseases.
Tsoumpra MK, Fukumoto S, Matsumoto T, Takeda S, Wood MJA, Aoki Y. EBioMedicine. 2019 Jul;45:630-645. doi: 10.1016/j.ebiom.2019.06.036. Epub 2019 Jun 27.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6642283/

Thursday, December 10, 2020 - 13:45
Clinical Pharmacology Studies Supporting Oligonucleotide Therapy Development: An Assessment of Therapies Approved and in Development Between 2012-2018

Clinical Pharmacology Studies Supporting Oligonucleotide Therapy Development: An Assessment of Therapies Approved and in Development Between 2012-2018.
Rogers H, Adeniyi O, Ramamoorthy A, Bailey S, Pacanowski M.
Clin Transl Sci. 2020 Dec 5. doi: 10.1111/cts.12945. Online ahead of print.
https://ascpt.onlinelibrary.wiley.com/doi/10.1111/cts.12945

Monday, December 7, 2020 - 10:08

Pages